

September 29, 2025

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir,

Reg : Press Release: Fischer Medical Ventures Reports 123% YoY Surge in Total Income for Q2 FY26 – Strengthens Position in India’s Fast-Growing MedTech Sector”

We enclose a press release regarding **“Fischer Medical Ventures Reports 123% YoY Surge in Total Income for Q2 FY26 – Strengthens Position in India’s Fast-Growing MedTech Sector”**, for dissemination.

Thanking you,
Yours Truly,
For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



ARAVINDKUMAR V
COMPANY SECRETARY & COMPLIANCE OFFICER



Fischer Medical Ventures Reports 123% YoY Surge in Total Income for Q2 FY26 *Strengthens Position in India's Fast-Growing MedTech Sector*

Mumbai– October 29, 2025: Fischer Medical Ventures Limited (FISCHER | 524743 | INE771F01041), one of the leading companies engaged in the business of developing innovative, cost-effective medical imaging, advanced diagnostics and point-of-care diagnostic solutions, has announced its unaudited financial results for Q2 & H1 FY26.

Key Consolidated Financial Highlights

Particulars (₹ Cr)	Q2 FY26	Q2 FY25	YoY	H1 FY26	H1 FY25	YoY
Total Income	88.79	39.88	↑ 122.64%	119.70	50.74	↑ 135.90%
EBITDA	18.74	0.72	↑ 2,511.72%	30.46	1.28	↑ 2,274.35%
EBITDA Margin %	21.10%	1.80%	↑ 1,930 BPS	25.45%	2.53%	↑ 2,292 BPS
Net Profit	13.96	0.29	↑ 4,659.63%	18.97	0.18	↑ 1,0664.64%
Net Profit Margin %	15.72%	0.74%	↑ 1,499 BPS	15.85%	0.35%	↑ 1,550 BPS
EPS (₹) (Diluted)	2.11	0.05	↑ 4,200.00%	2.87	0.03	↑ 9,466.67%

Commenting on the Results, Mr. Ravindran Govindan, Chairman of Fischer Medical Ventures Limited, said: “Q2 was a very strong quarter for Fischer, marking significant improvement across all operational and financial parameters. The steep rise in profitability reflects the scalability of our model, better product realization, and the growing acceptance of Fischer’s technology across India and overseas markets.

India’s MedTech and diagnostic industry is expanding rapidly, driven by government focus on indigenous manufacturing, preventive care, and AI-led healthcare solutions. Fischer is well aligned with these trends, leveraging its expertise in MRI systems, AI diagnostics, and digital health platforms to strengthen its position in this evolving landscape.

With our expanding footprint across Southeast Asia, new product launches, and advanced solutions such as SpinCare® and portable X-ray systems, we are confident of sustaining this growth momentum and creating long-term value for all”

Key Business Highlights

Acquires Strategic Property in Malaysia	<ul style="list-style-type: none">Acquired landmark mixed-use property in Malaysia to develop an Integrated Regional Healthcare HubExpand FMV’s presence across Southeast Asia
Public-Private Partnership in Indonesia	<ul style="list-style-type: none">Partnered City of Jember to deploy AI-powered portable X-ray systems

	<ul style="list-style-type: none"> • Supports “TB Free Jember by 2026” & TB elimination by 2030 projects valued at USD 10 million (approx.)
Global Innovation Licensing Milestone	<ul style="list-style-type: none"> • Secures full licensing in Indonesia, eligible to participate in End-TB Handheld X-ray Government Tender
Diagnostic Imaging Expansion in India	<ul style="list-style-type: none"> • Launched High-Resolution Open MRI at Sunray Scans, Chennai • Installed PICA 0.35T Open MRI at STNM Hospital, Sikkim
AI Innovation Recognition – NYB.AI (JV Partner)	<ul style="list-style-type: none"> • Won 1st Prize at SuperAI Genesis Global Competition • Recognized for AI-driven drug discovery platform (DTIGN) • Partners include NVIDIA, J&J Innovation, and HPE
Nanomedic – Operational & Regulatory Progress	<ul style="list-style-type: none"> • Completed Phase 1 MDR/MDD audit; Phase 2 due Oct 2025 • Preparing SpinCare® FDA filing; outcome expected Q4 FY26
SpinCare- Clinical Advancements	<ul style="list-style-type: none"> • Proven safe and effective in pediatric burns • Stanford trial showed strong tolerability, no adverse events

About Fischer Medical Ventures Limited

Fischer Medical Ventures Limited (FMVL, the “Company”) Incorporated in 1993, Fischer Medical Ventures Limited (FMV) is driving a global shift in healthcare through innovative, cost-effective medical imaging and advanced diagnostics. Beyond medical devices, FMV offers a wide range of point-of-care diagnostic solutions, enabling timely and accurate patient care. Leveraging expertise, resources, and strategic partnerships, the company is committed to enhancing accessibility, affordability, and progress in healthcare delivery, creating a meaningful impact on healthcare systems worldwide. **Headquartered in Chennai**, with a facility at the Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam, its subsidiary Fischer Medical Ventures Limited (FMVL) is the first Indian company recognized by CDSCO for indigenously manufacturing MRI systems.

FMVL focuses on medical diagnostics, digital health, and AI-powered healthcare software. Its product range includes MRI systems (0.35T & 1.5T), preventive health kiosks, e-health access points (E-HAPs), AI-based software for cancer and TB screening, handheld X-ray devices, SpinCare technology, nutraceuticals from plant extracts, and contactless mental health screening. Upcoming products include oncology and CT scan solutions.

FMVL aims to make healthcare accessible and affordable through innovation and data-driven solutions. Its 100% subsidiary FlynnCare Health Innovations Pvt. Ltd. provides digital platforms for community health screening and hospital connectivity.

In FY25, the company reported revenue of ₹ 111 Cr, EBITDA of ₹ 4 Cr & net profit of ₹ 1.21 Cr on consolidated basis



Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.